Bico Group Ab Class B · OMXSTO:BICO
Bico Group Ab Class B — Q1 2026 Earnings Presentation
31 slides from Bico Group Ab Class B's earnings presentation, Apr 29, 2026
Slide 1: Interim Report Q1 2026 Earnings Call
INT ERIM REPORT Q1 2026 EARNINGS CALL 2026-04-28 – W EDNESDAY, APRIL 29, 2026
Slide 2: Disclaimer
DISCLAIMER You must read the following before continuing. The following for publication, release or distribution in the United States, affect the extent to which a particular projection is real- ised. applies to this document and the information provided in this the United Kingdom, Australia, Canada
Slide 3: Earnings Call Agenda
Earnings Call Agenda Summary Q1 2026 Group Financial Performance Continuous Product Innovation Concluding Remarks Maria Forss Ewa Linsäter Q&A President & CEO CFO 3
Slide 4: Net Sales and Adjusted EBITDA Margin
Q1 2026 330 11 - 11 47 NET SALES ORGANIC SALES ADJUSTED EBITDA OPERATING CASH FLOW SEK m GROWTH SEK m SEK m % Q1 2025 - Q1 2026 Net sales and adjusted EBITDA margin Sales (SEKm) Adjusted EBITDA margin (%) 500 15.0% 451 450 10.0% 400 387 350 335 324 330 5.0% 300 0.0% 250 -5.0% 200 150 -10.0% 100 -15.
Slide 5: BICO's Portfolio Supports Drug and Diagnostic Development
BICO’s Portfolio Supports with Workflows Along Drug and Diagnostic Development to Automate Labs BICO’s current strengths and technologies are largely grouped into three fields Molecular biology Drug discovery Bioprocessing Next generation Assay development Single-cell proteomics sequencing Cell line
Slide 6: The Global Challenge
The Global Challenge Long and costly clinical stages combined with low success rate comprise a global challenge for the drug development industry Drug discovery Product development Process development Production > USD 2bn ~ 10% > 10 years Probability of approval Development costs Discovery to approv
Slide 7: AI Acceleration Shifts the Bottleneck to the Wet Lab
BICO AI Lab Automation Acceleration Shifts Provides the the Execution Bottleneck to & Validation the Wet Lab layer converting AI hypotheses into proven experimental evidence 02 THE CRITICAL LAYER 01 03 AI Hypothesis Generation AI-Powered Wet Lab Validated Evidence Automation Generative models and pr
Slide 8: Roadmap for AI-Powered Lab Automation with Green Button Go
AI Acceleration Shifts the Bottleneck to the Wet Lab Roadmap for AI -Powered Lab Automation with Green Button Go AVAILABLE TODAY NEXT-GEN ROADMAP DURABLE MOAT Assistive AI in Platform Crescendo: Scale & Orchestration Reliability · Integrity · Compliance Our AI Platform brings natural-language Develo
Slide 9: Purpose Vision Mission
Purpose Vision Mission BICO exists so therapies To enable life-science labs BICO leverages a global reach humanity sooner. to accelerate the portfolio of pioneering discoveries that change brands fusing automation, lives. intelligence, and data to unlock scientific discovery at scale. Trust Focus C
Slide 10: The Results of Automation Have Never Been More Important
The Results of Automation Have Never Been More Important REDUCING THE COST AND TIMELINE TO MARKETABLE DISCOVERIES IS IMPERATIVE Reduce downstream process and assay development by 75% AUTOMATION CAN 75% Increase existing equipment 400% capacity by 400% through parallel processing and variable-driven
Slide 11: BICO Leads the Way in Solving Challenges
BICO Leads the way in Solving the Challenges in Life Science with Speed, Accuracy, and Efficiency Speed • Reducing the time to find optimal candidates for treatment therapies • Driving forward a personalized approach in treatment • Enabling the development of physiologically relevant models Accuracy
Slide 12: Summary of Q1 2026
Summary of Q1 2026 1212
Slide 13: Summary Q1 2026
Summary I Q1 2026 CASH FLOW FROM NET SALES ADJUSTED EBITDA OPERATING ACTIVITIES SEK 330m SEK -11m SEK 47 m ADJUSTED ORGANIC SALES GROWTH NWC/LTM SALES EBITDA MARGIN 11% -3.4% 7% All numbers in this presentation refer to continuing operations if not otherwise stated. MatTek and Visikol have been clas
Slide 14: Group Financial Performance
Group Financial Performance 1414
Slide 15: Sales Development
Sales Development ( SEKm ) SEKm 500 -1,4%* 450 • Sales SEK 330m with 400 organic growth of 11 % 350 • Growth mainly driven by desktop instruments 300 Service&Other • The difference between sales 250 Consumables growth and organic sales 200 Instruments growth - mainly explained by a weaker US dollar
Slide 16: Adjusted EBITDA and Margin
Adjusted EBITDA ( SEKm ) and Margin (%) SEKm % 80 15% 13% • Adjusted EBITDA SEK 60 56 10% –11.4m corresponding to a margin of -3.4 percent 40 5% 5% • Restructring costs of SEK 20 17 0% 52.5m whereof SEK 30.2m -3% affected EBITDA 0 -5% -6% • Annualised savings of ca -11 -20 -20 -10% SEK 30m from rest
Slide 17: Cash Flow and Financial Position
Cash Flow and Financial Position • Cash flow from operating activities, SEK 47m • includes impact from changes in working capital of SEK 79m • Total cash flow during Q1 was SEK -547m • Issued secured senior bonds of EUR 40m • Previous existing bonds, originally issued in 2021, of SEK 1,008m was sett
Slide 18: Development in Net Working Capital
FINANCIAL PERFORMANCE Development in Net Working Capital between Q1 2025 and Q1 2026* SEKm 800 30.0% 600 20.0% 400 12.4% 12.5% 12.6% 10.9% WC Liabilities 10.0% 200 203 195 188 Other Receivables 169 7.3% 109 Accounts Receivables Inventories 0 0.0% Total NWC NWC / LTM Sales -200 -10.0% -400 -600 -20.0
Slide 19: BICO Issued Senior Secured Bonds
BICO Issued Senior Secured Bonds • Total nominal of EUR 40 million • Tenor of four years • The bonds were placed with a consortium of Swedish institutional investors • Supporting further growth and capture market recovery while naviating ongoing macroeconomic uncertainty 19
Slide 20: Continuous Product Innovation
Continuous Product Innovation 20 20
Slide 21: R&D Pipeline and Roadmap
Instrument Software R&D Pipeline & Roadmap Consumable Product Portfolio 2026 2027 2028 2029 Lab Automation Software Standardized Lab Automation Lab Automation Components Bioprinting Precision Dispenser Liquid Handling Single-cell Dispenser Live-cell Imaging Microscopes 21
Slide 22: AI-Powered VCD and Cell Counting on the UP.SIGHT
AI - Powered VCD & Cell Counting on the UP.SIGHT CYTENA’s UP.SIGHT 2nd GEN continues its evolution from a single-cell dispenser into an all-in-one CLD analytical instrument, consolidating fragmented steps in CLD workflows. 10× faster €20–30k / year time-to-result vs. sequential VCD on estimated savi
Slide 23: Launching Spring 2026
Launching spring 2026 AUTOMATED BEAD-BASED CLEAN-UP G.PURE GEN 2 The G.PURE GEN 2 from CYTENA, automates DNA purification, delivering rapid, reproducible, plastic tip-free sample cleanup for efficient NGS library preparation workflows. AUTOMATED NGS WORKSTATION G.STATION GEN 2 The G.STATION GEN 2 fr
Slide 24: AI Acceleration Shifts the Bottleneck to the Wet Lab
AI Acceeration Shifts the Bottleneck to the Wet Lab Roadmap for AI -Powered Lab Automation with Green Button Go AVAILABLE TODAY NEXT-GEN ROADMAP DURABLE MOAT Assistive AI in Platform Crescendo: Scale & Orchestration Reliability · Integrity · Compliance Our AI Platform brings natural-language Develop
Slide 25: Concluding Remarks
Concluding Remarks 25
Slide 26: BICO Vision and Strategic Agenda
BICO Vision and Strategic Agenda TO ENABLE LIFE SCIENCE LABS Vision TO ACCELERATE THE DISCOVERIES THAT CHANGE LIVES BICO leverages a global portfolio of pioneering brands Mission fusing automation, intelligence, and data to unlock scientific discovery at scale Enable end-to-end Further develop Ensur
Slide 27: Focus Areas 2026 for Profitable Growth
Focus Areas 2026 for Profitable Growth 1 Commercial Execution 2 R&D Pipeline Execution 3 Financial Discipline 27
Slide 28: Q&A
Q&A 28
Slide 29: 2026-04-28
2026-04-28
Slide 30: Financial Calendar Contact
Financial Calendar Contact MARIA FORSS, CEO AND PRESIDENT EWA LINSÄTER, CFO BICO GROUP AB BICO GROUP AB Phone: EA Elisabeth Lindell, +46 761 73 40 59 Phone: +46 766 333 233 E-mail: mf@bico.com E-mail: ewa.linsater@bico.com MAY 7, 2026 Annual General Meeting 2026 AUGUST 19, 2026 Q2 Report 2026 BICO s
Slide 31: 2026-04-28
2026-04-28